Plain-English translation of NCT07604103 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This research is studying how an influenza tetravaccine affects specific proteins in your blood when you have had both a heart attack and pneumonia. By measuring these proteins, researchers hope to better understand how your body is responding to these serious conditions and whether the vaccine influences that response. This could help doctors predict how well patients will recover and manage their care more effectively.
When patients have a heart attack and a lung infection at the same time, their bodies experience a strong inflammatory response that is hard to monitor with standard tests. Researchers want to know if the vaccine changes these markers and whether tracking these proteins could give doctors a better picture of what's happening inside the body.
You likely qualify if…
You likely don't qualify if…
You will receive one dose of either the influenza vaccine or a placebo (inactive shot), and your blood will be drawn at scheduled clinic visits to measure specific proteins that show how your body is responding. You will need to complete follow-up visits to allow researchers to track these markers over time. The study involves standard outpatient clinic appointments where blood samples are collected—no hospital admission is required after your initial stabilization.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Indonesia